Banner

What's New

Innovative resource for your improved understanding of
specialty diseases

Archives

Continuing to deliver on our vision and share disease insight with our clients, members of our proprietary panel of cancer treaters and the global cancer community, MDoutlook has developed the following insight into metastatic colorectal cancer (mCRC) in Germany.

MDoutlook’s analysis is based on data gathered in a recent web-based study with 82 medical oncologists and gastroenterologists. Their mCRC patient volume represents more than 5% of the 63,000 colorectal cancer patients diagnosed each year in Germany (2012 data: EUCAN Factsheet).

In this study, MDoutlook was able to collect information on patients in 1st Line of Treatment down to 5th+ Line of Treatment, separated out by KRAS Gene Mutation Status (Wild Type, Mutant) as shown in the image below. MDoutlook also collected specific treatment selections by Line of Treatment (not shared).

Patient Flow Chart mCRC in Germany - Summer 2014

Patient Flow Chart mCRC in Germany – Summer 2014

The MDoutlook Analyst Team concludes:

  • Percentage of mCRC patients treated in each line of therapy drops as line of therapy increases:
    ▪ 40% of patients are in 1st line of treatment
    ▪ ~30% are in 2nd line of treatment
    ▪ ~30% are in 3rd + line of treatment
  • Percentage of patients that receive active treatment in later lines of therapy (4th+ line) is lower than the patients in early therapy lines:
    ▪ Nearly all patients in 1st and 2nd line undergo active treatment
    ▪ A little over 90% of 3rd line patients receive active treatment
    ▪ Drops to 77% of 4th line and 61% of 5th+ line patients
  • Percentage of KRAS wild type mCRC patients are consistently higher than KRAS mutant across all therapy lines
  • MDoutlook has extensive experience in analyzing the European cancer market, focusing on both solid and liquid tumors. In the last few years, MDoutlook provided more than 30 clients with answers to who, what, when, where, and why of cancer treatment in Europe.

    Our work includes a wide range of topics focused on major malignancies (breast, colorectal, lung, melanoma, prostate, CLL, NHL), more targeted malignancies (liver, thyroid, ALL, HL) and other critical topics (market access, supportive care, management of adverse events).

    Contact us to discuss how MDoutlook will support your disease intelligence needs, through customized and syndicated studies, ThoughtLeader identification and physician engagement.

     

    MDoutlook has extensive experience in analyzing the European cancer market, focusing on both solid and liquid tumors. In the last few years, MDoutlook provided more than 30 clients with answers to who, what, when, where, and why of cancer treatment in Europe.

    Recent work addressed business critical issues in:

    • Major malignancies: breast, colorectal, lung, melanoma, prostate, CLL, NHL
    • Targeted malignancies: liver, thyroid, ALL, HL and others
    • Management of cancer: market access, supportive care, management of adverse events

    Insight from a recent European study in Chronic Lymphocytic Leukemia (CLL | n=100) prompted further analysis shared below:

    Unmet needs as reported by 100 medical oncologists  from the EU5

    Unmet needs as reported by 100 medical oncologists from the EU5

    Contact us to discuss how MDoutlook can support your disease intelligence needs, through customized and syndicated studies, ThoughtLeader identification and physician engagement.

    MDoutlook identifies and engages with cancer treaters of all disciplines, clinical interest, practice setting, and ThoughtLeader status. Since our start in 2008, we have profiled more than 6,500 global oncology ThoughtLeaders, identifying their National, Local and Referral ThoughtLeader rankings.

    With the ASCO Breast Cancer Symposium in San Francisco this month, we thought it useful to share some highlights of our US-focused ThoughtLeader research in breast cancer:

    • 125+ National ThoughtLeaders
    • 700+ Local ThoughtLeaders
    • 700+ Referral ThoughtLeaders – “Who do you refer your patients to for treatment?” 

    The top 8 referral ThoughtLeaders in Breast Cancer in the US
    Top 8 Referral ThoughtLeaders in Breast Cancer

    Further analysis of the physician referral patterns, yields the following the Top US referral institutions for breast cancer:

    1. Memorial Sloan Kettering Cancer Center
    2. Dana-Farber Cancer Institute
    3. University of California San Francisco Medical Center
    4. University of Texas MD Anderson Cancer Center
    5. Mayo Clinic
    6. Stanford University Hospital
    7. Duke University Medical Center
    8. Northwestern Memorial Hospital
    9. UCLA Medical Center
    10. University of Michigan Medical Center

    MDoutlook’s methodology utilizes a proprietary and integrated peer-nomination system allowing for prominence of clinical reputation via peer ranking. Employing the unique MDoutlook ThoughtLeader Attribute Dial™, additional criteria are weighed such as:

    • Publication and clinical trial
    • Leadership
    • Professional profile
    • Public profile
    • And other client-specific factors

    For more information or to discuss how we can support your work in breast cancer and other areas of oncology, please contact Craig Krugman (+1.404.452.5988). Or do connect with him at the upcoming ASCO Breast Cancer meeting in San Francisco.

    At the recent annual ASCO meeting in Chicago we received the highest compliment from a client you can expect: we were awarded “Best Practice” for a ThoughtLeader identification and mapping project that we completed earlier in the year.

    This compliment was bestowed upon us by the European headquarters of a US-based major, leading pharmaceutical company with a long presence in oncology. The project was focused on a new and exciting research area within oncology.

    Some samples from our report are shown below. The network visualization and especially our exclusive and unique MDoutlook ThoughtLeader Attribute Dial™ are highly appreciated by our clients.

    Contact us by email or via the contact form for more information or a proposal in your interest area.

    MDoutlook ThoughtLeader Dashboard - Exclusive Attribute Dial

    MDoutlook ThoughtLeader Dashboard – Exclusive Attribute Dial

    MDoutlook TL Dashboard - Professional Network Visualization

    MDoutlook TL Dashboard – Professional Network Visualization